Boknik, P. et al. 2000. Protein phosphatase activity is increased in a rat model of long-term beta-adrenergic stimulation. Naunyn Schmiedebergs Arch Pharmacol. 362(3), pp.222-31.
Boknik, P. et al. 2001. Enhanced protein phosphorylation in hypertensive hypertrophy. Cardiovascular Research. 51(4), pp.717-728.
Bye, A. et al. 2008. Carbon monoxide levels experienced by heavy smokers impair aerobic capacity and cardiac contractility and induce pathological hypertrophy. Inhalation Toxicology. 20(7), pp.635-646.
Chakraborty, A. et al. 2014. Inhibition of CaMKII does not attenuate cardiac hypertrophy in mice with dysfunctional ryanodine receptor. PLoS One. 9(8), pe104338.
Chen, X.W. et al. 2011. Calcium influx through Cav1.2 is a proximal signal for pathological cardiomyocyte hypertrophy. Journal of Molecular and Cellular Cardiology. 50(3), pp.460-470.
Denipote, F. et al. 2011. Influence of Taurine on Cardiac Remodeling Induced by Tobacco Smoke Exposure. Cellular Physiology and Biochemistry. 27(3-4), pp.291-298.
Guinto, P.J. et al. 2009. Temporal and mutation-specific alterations in Ca2+ homeostasis differentially determine the progression of cTnT-related cardiomyopathies in murine models. Am J Physiol Heart Circ Physiol. 297(2), pp.H614-26.
Song, L.S. et al. 2005. Paradoxical cellular Ca2+ signaling in severe but compensated canine left ventricular hypertrophy. Circulation Research. 97(5), pp.457-464.
Badrilla is a manufacturer of outstanding antibodies against cardiac proteins and phospho-proteins, and the manufacturer of leading kits for the study of protein S-palmitoylation.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.I agree